CIK 0001690585 · Non-accelerated filer<br>Smaller reporting company
Dianthus Therapeutics, Inc. /DE/
Sign in to watch- Ticker
- DNTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 929-999-4055
- Business address
- 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
- Former names
- Magenta Therapeutics, Inc.
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 8-K Event Results of operations
- 10-Q Report Quarterly Report
- 8-K Event Results of operations · Other events
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Other acquisition Director acquired 4,100 shares (other)
- 4 Open-market sale Chief People Officer sold 5,736 shares at $6.73 ($38,603)
- 4 Open-market sale See Remarks sold 5,736 shares at $6.73 ($38,603)
- 4 Open-market sale Chief Commercial Officer sold 6,238 shares at $6.73 ($41,982)
- 4 Open-market sale See Remarks sold 14,340 shares at $6.73 ($96,508)
- 4 Open-market sale See Remarks sold 6,103 shares at $6.73 ($41,073)
- 4 Open-market sale See Remarks sold 5,736 shares at $6.73 ($38,603)
- 4 Open-market sale Chief Technical Officer sold 5,694 shares at $6.73 ($38,321)
- 4 Grant or award See Remarks acquired 20,000 shares (grant or award)
- 4 Grant or award Chief People Officer acquired 20,000 shares (grant or award)
Page 20 of 33 · 660 filings